Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.36 |
| ▸ | AKT1 | P31749 | 2/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | KIF5B | P33176 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | ILK | Q13418 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.35 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449757 | 0.87 | STK17A (0.42) | RETKIF5BPOLBFLT3ADORA2A | |
| SCHEMBL3451732 | 0.87 | RET (0.39) | RETKIF5BPOLBFLT3ADORA2A | |
| SCHEMBL3447677 | 0.86 | MAP4K4 (0.40) | RETKIF5BPOLBFLT3ADORA2A | |
| SCHEMBL3449074 | 0.85 | FLT3 (0.44) | RETKIF5BPOLBFLT3ADORA2A | |
| SCHEMBL3450353 | 0.85 | RET (0.40) | RETKIF5BPOLBFLT3ADORA2A | |
| SCHEMBL3449219 | 0.84 | KCNH2 (0.46) | RETKIF5BPOLBFLT3ADORA2A | |
| SCHEMBL3449785 | 0.84 | ADORA2A (0.40) | RETKIF5BPOLBFLT3ADORA2A | |
| SCHEMBL3450369 | 0.83 | RET (0.42) | RETKIF5BPOLBFLT3ADORA2A | |
| SCHEMBL3449257 | 0.83 | ADORA2A (0.41) | RETKIF5BPOLBFLT3ADORA2A | |
| SCHEMBL3448668 | 0.82 | CDK1 (0.41) | RETKIF5BPOLBFLT3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | ROCK2 4464/4885AKT1 3483/4885RET 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.